Benzinga | Jul 19, 2021 06:06AM EDT

Gilead's Lenacapavir Shows High Rates Of Virologic Suppression In Heavily Treated HIV Patients

* Gilead Sciences Inc (NASDAQ:GILD) announced new Phase 3 data from the ongoing CAPELLA trial evaluating lenacapavir, its investigational, long-acting HIV-1 capsid inhibitor.

* The data were presented at the 11th International AIDS Society (IAS) Conference on HIV Science.

* The findings demonstrate that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high rates of virologic suppression at Week 26 in people with multi-drug resistant HIV.

* In this patient population, 81% (n=29/36) of participants receiving the lenacapavir combo regimen achieved an undetectable viral load at Week 26.

* Last month, Gilead submitted a marketing application to the FDA for lenacapavir.

* If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.

* The Company also shared announced long-term Biktarvy data showing high efficacy and durable viral suppression in untreated HIV patients.

* Price Action: GILD shares closed at $68.63 on Friday.